Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 2/20 | 0.64 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.57 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | FLT1 | P17948 | 3/20 | 0.53 |
| ▸ | FLT4 | P35916 | 3/20 | 0.53 |
| ▸ | KDR | P35968 | 3/20 | 0.53 |
| ▸ | HRH1 | P35367 | 2/20 | 0.51 |
| ▸ | CCR3 | P51677 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | LIPE | Q05469 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31456338 | 0.84 | ALDH1A1 (0.67) | KCNA1KCNAB1LMNAPOLBALDH1A1 | |
| SCHEMBL14794998 | 0.84 | POLB (0.54) | LMNAPOLBALDH1A1KMT2AGAA | |
| Tolpyrramide SCHEMBL667821 | 0.83 | KMT2A (0.64) | KCNA1KCNAB1LMNAPOLBHRH1 | |
| SCHEMBL30549042 | 0.82 | STS (0.58) | STSKCNA1KCNAB1FLT1FLT4 | |
| SCHEMBL25293555 | 0.81 | KMT2A (0.54) | STSKCNA1KCNAB1LMNAPOLB | |
| Glypinamide SCHEMBL343885 | 0.80 | ALDH1A1 (0.74) | KCNA1KCNAB1LMNAFLT1FLT4 | |
| SCHEMBL25294154 | 0.79 | KMT2A (0.51) | STSKCNA1KCNAB1LMNAPOLB | |
| Glyclopyramide SCHEMBL49354 | 0.78 | ALDH1A1 (0.71) | STSKCNA1KCNAB1LMNAFLT1 | |
| Glyclopyramide SCHEMBL15669226 | 0.78 | ALDH1A1 (0.71) | STSKCNA1KCNAB1LMNAFLT1 | |
| SCHEMBL29178289 | 0.77 | SMN1; SMN2 (0.57) | STSLMNAFLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049736-A1 | SULFONAMIDE DERIVATIVES AND THEIR USE AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | THE US SECRETARY DEPARTMENT OF HEALTH (US) | 2025-02-13 | — | — | US | disclosed |
| EP-4448491-A2 | N-((ADAMANTAN-1-YL)CARBAMOYL)-BENZENESULFONAMIDE DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF HYPERTENSION | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023114366-A2 | SULFONAMIDE DERIVATIVES AND THEIR USE AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049736-A1 | SULFONAMIDE DERIVATIVES AND THEIR USE AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, FAAH, ECE1 | STS 16/4885KCNA1 1183/4885KCNAB1 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.